<- Go Home
Nuvation Bio Inc.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.
Market Cap
$893.3M
Volume
2.9M
Cash and Equivalents
$248.0M
EBITDA
$201.5M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$4.0M
Profit Margin
27.54%
52 Week High
$3.46
52 Week Low
$1.54
Dividend
N/A
Price / Book Value
2.40
Price / Earnings
-4.15
Price / Tangible Book Value
2.48
Enterprise Value
$343.4M
Enterprise Value / EBITDA
1.68
Operating Income
$200.4M
Return on Equity
44.84%
Return on Assets
20.17
Cash and Short Term Investments
$607.7M
Debt
$57.8M
Equity
$372.9M
Revenue
$14.4M
Unlevered FCF
$179.6M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium